| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Jul―15 |
GeoVax Advances COVID-19 Vaccine with Up to $45M from BARDA |
Alex Philippidis |
| 2 |
[GO] |
2024―Apr―17 |
Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody |
Alex Philippidis |
| 3 |
[GO] |
2023―Nov―28 |
Pick Up the Pieces: Invivyd Engineers New COVID-19 Monoclonal Candidate |
Alex Philippidis |
| 4 |
[GO] |
2023―Feb―09 |
Developing the Next Generation of SARS-CoV-2 Vaccines |
Mark J. Newman |
| 5 |
[GO] |
2022―Dec―28 |
Wide Shot: Jacob Glanville Pursues Broad-Spectrum Vaccines vs. Pandemics |
Alex Philippidis |
| 6 |
[GO] |
2022―Dec―20 |
Pfizer and Clear Creek Bio to Collaborate on COVID-19 Antiviral Research Program |
Jonathan D Grinstein |
| 7 |
[GO] |
2022―Nov―02 |
How COVID-19 Forever Changed the In Vitro Diagnostics Marketplace |
|
| 8 |
[GO] |
2022―Aug―10 |
StockWatch: Humanigen Wilts after COVID-19 Antibody Fails NIH Trial |
Alex Philippidis |
| 9 |
[GO] |
2022―Aug―10 |
StockWatch: Valneva, Novavax Stocks Swing with COVID-19 Developments |
Alex Philippidis |
| 10 |
[GO] |
2022―Apr―08 |
GEN Edge StockWatch: Investors Warm to Moderna's COVID-19 Sales, Vaccine Updates |
Alex Philippidis |
| 11 |
[GO] |
2022―Feb―14 |
AbCellera, Lilly Advance Next-Generation Antibody vs. COVID-19 |
Alex Philippidis |
| 12 |
[GO] |
2022―Feb―14 |
In the Chips: Draper Adapting Tissue Culture Platform vs. COVID-19 |
Alex Philippidis |
| 13 |
[GO] |
2022―Feb―14 |
Close to the Edge: Regeneron's George Yancopoulos and Aris Baras Discuss Company, COVID-19 |
Alex Philippidis, Kevin Davies |
| 14 |
[GO] |
2022―Feb―14 |
The COVID-19 Pandemic: Lessons for the Future |
Justin Sanchez |
| 15 |
[GO] |
2022―Feb―14 |
Now Hiring: COVID-19, VC Surge Fuels Biotech Job Gains in Massachusetts and California |
Alex Philippidis |
| 16 |
[GO] |
2022―Feb―14 |
Off Message: Dyadic Fights COVID-19 with a Fungus |
Alex Philippidis |
| 17 |
[GO] |
2022―Feb―14 |
Beyond COVID-19: AbCellera Partners with Moderna to Develop mRNA-Encoded Antibodies |
Alex Philippidis |
| 18 |
[GO] |
2022―Feb―14 |
Pardes Biosciences Advances Oral Antiviral Drug for SARS-CoV-2 Infections |
Jonathan D. Grinstein |
| 19 |
[GO] |
2022―Feb―14 |
From Pandemic to Pipeline: What's Next for Moderna? |
Alex Philippidis |
| 20 |
[GO] |
2022―Feb―07 |
A ‘Human' Touch vs. COVID-19 |
Alex Philippidis |
| 21 |
[GO] |
2022―Feb―07 |
Obsidian's SWFT Response to COVID-19 |
Alex Philippidis |
| 22 |
[GO] |
2022―Feb―07 |
Gene Therapy Pioneer, Regeneron Partner on Nasal Spray vs. COVID-19 |
Alex Philippidis |
| 23 |
[GO] |
2022―Feb―07 |
$500M Merger Boosts NeuroRx VIP Guided Missile vs. COVID-19 |
Alex Philippidis |
| 24 |
[GO] |
2022―Feb―07 |
Athersys Stem Cell Therapy Targets Top Cause of COVID-19 Deaths |
Alex Philippidis |
| 25 |
[GO] |
2022―Feb―07 |
Massachusetts Biopharma Industry Weathers COVID-19 Impacts on Jobs, Financing |
Alex Philippidis |
| 26 |
[GO] |
2022―Feb―07 |
Putting COVID-19 on the ‘Map' |
Alex Philippidis |
| 27 |
[GO] |
2022―Feb―07 |
COVID-19 Puts Spotlight on Artificial Intelligence |
Jonathan Block |
| 28 |
[GO] |
2022―Feb―07 |
One COVID-19 Shot, Two Approaches |
Alex Philippidis |
| 29 |
[GO] |
2022―Feb―07 |
Beyond the Spike: The COVAXX Approach to a COVID-19 Vaccine |
|
| 30 |
[GO] |
2022―Feb―07 |
Quartet of COVID-19 Vaccine Candidates Head toward the Homestretch |
Alex Philippidis |
| 31 |
[GO] |
2022―Feb―07 |
GenapSys Pursues Partnership with China CDC to Detect Coronavirus |
Alex Philippidis |
| 32 |
[GO] |
2022―Feb―07 |
Assessing Coronavirus Impact on Wall Street |
Alex Philippidis |
| 33 |
[GO] |
2022―Feb―07 |
Mammoth Pursues Coronavirus Partnership as It Grows CRISPR Ambitions |
Alex Philippidis |
| 34 |
[GO] |
2022―Feb―07 |
Synthetic Data for a Real Pandemic |
Alex Philippidis |
